132 related articles for article (PubMed ID: 22961832)
1. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
Proschan M; Ford CE; Cutler JA; Graumlich JF; Pavlik V; Cushman WC; Davis BR; Alderman MH; Gordon D; Furberg CD; Franklin SS; Blumenthal SS; Castaldo RS; Preston RA;
Stat Med; 2013 Feb; 32(5):884-97. PubMed ID: 22961832
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
[TBL] [Abstract][Full Text] [Related]
3. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
[TBL] [Abstract][Full Text] [Related]
4. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
[TBL] [Abstract][Full Text] [Related]
6. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
[TBL] [Abstract][Full Text] [Related]
7. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
8. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
[TBL] [Abstract][Full Text] [Related]
9. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
[TBL] [Abstract][Full Text] [Related]
10. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
[TBL] [Abstract][Full Text] [Related]
11. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
12. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
Cushman WC; Ford CE; Cutler JA; Margolis KL; Davis BR; Grimm RH; Black HR; Hamilton BP; Holland J; Nwachuku C; Papademetriou V; Probstfield J; Wright JT; Alderman MH; Weiss RJ; Piller L; Bettencourt J; Walsh SM;
J Clin Hypertens (Greenwich); 2002; 4(6):393-404. PubMed ID: 12461301
[TBL] [Abstract][Full Text] [Related]
13. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
Düsing R
Dtsch Med Wochenschr; 2003 Jan; 128(5):214-6. PubMed ID: 12557115
[No Abstract] [Full Text] [Related]
14. Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension.
Heckman GA; Psaty BM
ACP J Club; 2003; 139(3):A15; author reply A15. PubMed ID: 14594435
[No Abstract] [Full Text] [Related]
15. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Wang JG; Yan P; Jeffers BW
J Am Soc Hypertens; 2014 May; 8(5):340-9. PubMed ID: 24685006
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Reisin E; Graves JW; Yamal JM; Barzilay JI; Pressel SL; Einhorn PT; Dart RA; Retta TM; Saklayen MG; Davis BR;
J Hypertens; 2014 Jul; 32(7):1503-13; discussion 1513. PubMed ID: 24842697
[TBL] [Abstract][Full Text] [Related]
17. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.
Davis BR; Cutler JA; Furberg CD; Wright JT; Farber MA; Felicetta JV; Stokes JD;
Ann Intern Med; 2002 Sep; 137(5 Part 1):313-20. PubMed ID: 12204014
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
Scheen AJ; Krzesinski JM
Rev Med Liege; 2003 Jan; 58(1):47-52. PubMed ID: 12647599
[TBL] [Abstract][Full Text] [Related]
19. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
JAMA; 2008 Jan; 299(3):296-307. PubMed ID: 18212314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
